Recent Updates
Recently added Catalysts
TMDX Positive Sentiment

TransMedics to Report Third Quarter 2023 Financial Results on November 6, 2023 TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Key Takeaway: TransMedics Group, Inc. is set to release its third quarter 2023 financial results on November 6, 2023, after market close. The company, known for its innovations in organ transplant therapy, will also host a conference call at 4:30 p.m. ET. Investors can join the call through dedicated phone lines or via a webcast available on TransMedics' website. This report follows the company's mission to enhance organ viability and utilization in transplantation for patients with severe organ failure.
Price reaction · baseline $41.37 (2023-10-20 close) · clean, no other TMDX news in the window
day 0 close
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • TransMedics is leading in organ transplant technology.
  • The upcoming financial results may indicate growth opportunities.
  • The company's efforts address significant unmet medical needs.

Full Press Release Details

ANDOVER, Mass. , Oct. 23, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2023 after market close on Monday, November 6, 2023 . The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT .
Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung , and liver failure.

Frequently Asked Questions

When will TransMedics release its Q3 2023 financial results?

TransMedics will release its Q3 2023 financial results on November 6, 2023.

What time is the TransMedics Q3 earnings call?

The earnings call will begin at 4:30 p.m. ET on November 6, 2023.

How can investors listen to the conference call?

Investors can call (866) 807-9684 domestically or (412) 317-5415 internationally.

Where can I find the webcast of the earnings call?

The live and archived webcast will be available on TransMedics' 'Investors' website section.

What does TransMedics specialize in?

TransMedics specializes in organ transplant technology, particularly for heart, lung, and liver.

Last updated: Oct 23, 2023